Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Receivables (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Change in Receivables for 11 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 201.32% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 million, a 212.67% increase, with the full-year FY2025 number at $7.6 million, up 246.68% from a year prior.
  • Change in Receivables was -$2.3 million for Q4 2025 at Aytu Biopharma, down from $2.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $10.5 million in Q1 2025 to a low of -$6.5 million in Q3 2021.
  • A 5-year average of $120894.7 and a median of -$118000.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: crashed 2775.45% in 2022, then skyrocketed 2025.42% in 2024.
  • Aytu Biopharma's Change in Receivables stood at $1.3 million in 2021, then crashed by 277.6% to -$2.4 million in 2022, then surged by 95.04% to -$118000.0 in 2023, then surged by 2025.42% to $2.3 million in 2024, then plummeted by 201.32% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Change in Receivables are -$2.3 million (Q4 2025), $2.1 million (Q3 2025), and -$4.7 million (Q2 2025).